Basal insulin peglispro (BIL) comprises insulin lispro covalently bound to a 20-kDa polyethylene glycol (PEG) at lysine B28. The biologic fate of BIL and unconjugated PEG were examined in rats given a single 0. 
I after subcutaneous and intravenous administration. The half-lives of 14 C after BIL and PEG dosing were similar. The clearance of immunoreactive BIL was 2.4-fold faster than that of 14 C and 1.6-fold faster than 125 I. After a subcutaneous dose of BIL, immunoreactive BIL accounted for 31% of the circulating 125 I and 16% of the circulating 14 C, indicating extensive catabolism of BIL. Subcutaneous bioavailability of BIL was 23%-29%; bioavailability for unconjugated PEG was 78%. For unconjugated PEG, most of the 14 C dose was recovered in urine. For BIL, ‡86% of 125 I was
Introduction
Basal insulin peglispro (BIL, LY2605541) is a novel, PEGylated insulin lispro that has a large hydrodynamic size (Beals et al., 2009) . The compound has a covalently bonded 20-kDa polyethylene glycol (PEG) attached to insulin lispro through a urethane linkage on the lysine at position 28 in the B-chain (Moore, et al., 2014) . The hydrodynamic diameter is 7.8 6 0.4 nm, a diameter 4 times larger than that of insulin lispro and analogous to the size of an ;75-kDa globular protein. In contrast, insulin lispro is a rapidacting analog of insulin (Humalog, 1996) in which the amino acid proline at B28 has been replaced with lysine and the lysine at B29 has been replaced by proline, yielding a molecular weight of 5.8 kDa.
PEGylation of protein compounds in development as pharmaceutical agents has resulted in novel therapeutic agents with modified pharmacokinetic (PK) profiles that may improve their therapeutic potential (Webster et al., 2007 (Webster et al., , 2009 Fishburn, 2008) . BIL has a prolonged duration of action compared with insulin lispro that is related to a delay in insulin absorption and a reduction in clearance. BIL is currently in phase 3 studies for the treatment of patients with type 1 or type 2 diabetes mellitus.
There are many PEGylated therapeutic compounds either in drug development or currently used in the pharmaceutical drug marketplace; however, little is known about the biologic fate of the PEG moiety associated with PEGylated proteins. The PEG moieties used in currently available drugs range in size from a few hundred daltons to 40-kDa PEG, and some molecules have multiple PEG moieties attached (e.g., pegloticase has 40 10-kDa PEG moieties attached). The size of the PEG moiety has been reported to affect the elimination of the PEG (Webster et al., 2009) ; however, little information is available on how the drug or protein attached to the PEG moiety can affect the disposition of the different PEGs.
Tracking the metabolic fate of the PEG moiety is challenging because PEG has no UV chromophore, is nonfluorescent, has few high-affinity antibodies, and is difficult to ionize. In addition, highmolecular-weight PEGs (.30 kDa) are refractory to mass spectrometry (MS) analyses because of their polydispersed nature (Wang et al., 2012a) . NMR spectroscopy has been used to analyze the biologic fate of a PEGylated protein; however, a full mass balance could not be established with NMR spectroscopy, and these experiments could not tease apart the fates of the intact molecule and metabolites with PEG attached. There are reports of studies using immunoblotting with antibodies to PEG combined with NMR spectroscopy to assess the tissue uptake of a 40-kDa PEG moiety attached to insulin (Elliott et al., 2012 (Wang et al., 2012a) , 2 Â 20-kDa PEGylated [
14 C]peginesatide (Woodburn et al., 2012 (Woodburn et al., , 2013 , 46-kDa PEGylated [ 3 H]neuromedin-U receptor agonist (Zou et al., 2013) , and 30-kDa PEGylated [
125 I]erythropoietin (Wang et al., 2012b C label was placed on carbons 5 through 8 on the 20-kDa PEG from the urethane bond in the BIL. Lactoperoxidase was used to iodinate the tyrosines in the lispro portion of BIL, and free iodine was removed from the preparation. The specific activity of the 14 C-labeled BIL was 7.89 mCi/mg, the radiopurity was 97%, and the chemical purity was 95%-99% by high-performance liquid chromatography (HPLC In the study evaluating the biologic fate of unconjugated PEG, male rats were assigned to four groups: two groups received the intravenous dose, and two groups received the subcutaneous dose. For each dose paradigm, one of the two groups was for PK sampling and one was for mass balance.
Dosing and Sample Collection. For both studies, the volume of radiolabeled dose formulation to be administered to each rat was calculated by using the rat's body weight on the day of dose administration. The intravenous dose was administered via a tail vein, and the subcutaneous dose was administered in the intrascapular region. Rats were not fasted and had immediate access to food after dosing.
BIL doses were ;0.5 mg/kg (19.4 nmol/kg) for the intravenous dose and 2 mg/kg (77 nmol/kg) for the subcutaneous dose. The vehicle for the BIL study was 16.5 mM Tris, 29 mM m-cresol, 128 mM NaCl, and 0.39 mM zinc oxide at pH 7.3 in sterile water for injection. The 14 C radioactive doses were 4.35 mCi/kg for the intravenous dose and 18.1 mCi/kg for the subcutaneous dose. The 125 I radioactive doses were 118 mCi/kg for the intravenous dose and 464 mCi/kg for the subcutaneous dose. Starting ;48 hours before dose administration through the day of dose administration, the rats in the [ 125 I]BIL groups received water containing 20 mM sodium iodide ad libitum. In the unconjugated PEG study, the dose was 10 mg/kg (500 nmol/kg) i.v. and s.c. and the vehicle was phosphate-buffered saline. The dose was ;51 mCi/mg.
Blood for serum samples for the BIL study was collected via a jugular vein at 1, 3, 6, 9, 12, 24, 48, 72, 96, 120, 144, 168, 192, 240, and 336 C]BIL, serum from two rats from each time point was pooled to yield a total of three samples. In the unconjugated PEG study, blood for plasma was collected via a jugular vein before dosing and at 6, 24, 48, 72, 96, 120, 144, 168, 192, 240, 288 , and 336 hours after dosing from all animals at each time point in the PK groups (n = 4 samples per time point). Urine was collected from 0 to 12 and 12 to 24 hours after dosing (BIL study only) and at 24-hour intervals through 336 hours after dosing from four animals in each group. Feces were collected at 24-hour intervals through 336 hours after dosing from four animals in each group. Carcasses were collected at the end of 2 weeks.
Determination of Radioactivity. Concentrations of radioactivity in plasma, serum, urine, feces, cage rinse, cage wash, cage wipe, and residual carcass were determined using liquid scintillation spectrometry for 14 C. Plasma, serum, and urine were counted directly by using Ultima Gold XR scintillation cocktail. Feces were homogenized with a 1:1 ethanol/water solvent, and aliquots of the homogenates were combusted using a Packard Instrument Company (Downers Grove, IL) Model 307 Sample Oxidizer; the resulting 14 CO 2 was trapped with a mixture of Permafluor and Carbo-Sorb. Carcasses were digested in 1 N NaOH with ethanol before counting.
Concentrations of 125 I were determined in serum, urine, feces, cage rinse, cage wash, cage wipe, and residual carcass using solid scintillation spectrometry with a PerkinElmer Wallac 1480 Wizard. Urine samples from [ 125 I]BIL-dosed rats were analyzed by solid scintillation spectrometry before and after trichloroacetic acid (TCA) precipitation of proteins. To precipitate the proteins in urine, a 1% solution of bovine serum albumin and then cold 50% TCA were added. Samples were mixed gently and then allowed to sit for ;30 minutes at 4°C. Cold 10% TCA was added, samples were centrifuged, and the supernatants were discarded. The pellets were analyzed by solid scintillation spectrometry. Feces were homogenized with 1:1 ethanol/water, and an aliquot was counted. The carcass was digested with 1 N NaOH until dissolved, and ethanol was added for homogenization.
Determination of BIL in Serum and Urine. The concentrations of immunoreactive BIL in serum and urine were determined by using a validated enzyme-linked immunosorbent assay (ELISA) at Charles River Laboratories (Senneville, QC, Canada). A purified guinea pig anti-human insulin antibody (Eli Lilly and Co.) was coated onto a black Nunc MaxiSorp plate (Thermo Fisher, Pittsburgh, PA), and I-Block (Life Technologies, Grand Island, NY) solution was used to block free sites. Samples were loaded into the wells of the plate, and BIL was allowed to bind to the immobilized insulin antibody. The bound complex was detected by addition of rabbit monoclonal anti-PEG-biotin antibody (Abcam, Cambridge, MA). Following a wash step, peroxidaseconjugated streptavidin was added to the plate and signal was produced by adding QuantaBlu substrate (Thermo Scientific, Waltham, MA). The fluorescence signal was then measured at an excitation wavelength of 320 nm and an emission wavelength of 420 nm. The concentration of the samples was extrapolated from a standard curve fitted with a 5-PL equation, with a weighting factor of 1/Y 2 . The concentrations of BIL in the calibration standards, quality control samples, and study samples were directly proportional to the fluorescence measured in the wells of the plate.
The quantitative range for the serum assay was 75-500 pM, and for urine it was 30-500 pM. Samples with higher concentrations were analyzed after dilution of the sample. The percentage relative error, a measure of accuracy, was ,13% for serum and ,5% for urine. The percentage relative S.D., a measure of precision, was ,25% for both serum and urine assays.
Characterization of Serum and Urine PEG-Derived Products Using Liquid Chromatography-MS. The serum and urine profiles of [ 14 C]PEGderived products after subcutaneous administration of BIL were assessed by using a modified liquid chromatography (LC)-MS method described by Liu et al. (2013) for characterizing PEG and its related products in biologic matrixes. This method provided information regarding the identity of the products but was not used to quantitate the products. Serum samples and urine samples from rats in each group were each pooled by time point, and a 50-ml aliquot was mixed with 75 ml of 0.1% trifluoroacetic acid (TFA) in acetonitrile. After centrifugation, a 50-ml aliquot of the supernatant was mixed with 25 ml of 0.1% formic acid in water. The sample was centrifuged at 4000 rpm for 20 minutes at 4°C, and the supernatant was injected onto the chromatographic system.
A combination of intact and in-source fragmentation (ISF) techniques was applied to the MS analyses. Intact mass of the PEGylated products was obtained using a PLRP-S column (100 Â 0.3 mm) at 85°C with a binary gradient consisting of mobile phase A (0.01:100, TFA/water) and mobile phase B (0.01:100, TFA/water). The binary gradient was set up for a programmed elution profile of (time, %B) (0.00, 40) (2.00, 40) (2.05, 50) (16.0, 65) (16.05, 95) (17.00, 95) (17.05, 40) (22.00, 40) at a flow of 15 ml/min. The effluent from the chromatographic system was mixed with the effluent from a secondary pump delivering 3.5 ml/min of 0.5:50:50 diethylmethyl amine/water/ acetonitrile to provide charge reduction. The neutralized effluent was connected to a Micromass Synapt Q-TOF mass spectrometer (Waters, Inc., Milford, MA) for detection in the positive ion mode. Post-column neutralization was used for analyses of intact PEGylated products.
ISF MS/MS confirmation of the PEGylated products was obtained by using a similar chromatographic system described above without the post-column neutralization. The chromatographic system was connected directly to the Micromass Synapt Q-TOF mass spectrometer for mass spectral detection in the positive-ion mode. The eluent from the LC was introduced into the Q-TOF using an electrospray source.
For the post-column neutralization analyses and the ISF, data from the Q-TOF mass spectrometer were collected using MassLynx (version 4.1; Waters, Inc.) and MaxEnt1 (Waters, Inc.) deconvolution software.
Data Analyses. The key PK parameters reported for radioactivity in serum or plasma and for immunoreactive BIL in serum included maximum concentration (C max ), the time to reach maximum concentration (T max 
Results
Pharmacokinetics. Following intravenous administration, the serum CL of immunoreactive BIL was ;2.4-fold greater than the CL of 14 C radioequivalents and 1.6-fold greater than the CL of 125 I radioequivalents (Table 1 ). The CLs of immunoreactive BIL after 14 C dosing and 125 I dosing were similar, although the t 1/2 values appeared to differ. Immunoreactive BIL was quantifiable longer after 125 I administration and so appears to have a longer elimination phase. The mean V d of immunoreactive BIL was ;2.4-fold lower than the V d of total 125 I radioactivity in serum and 47-fold lower than that of 14 C radioactivity in serum.
Following subcutaneous administration of 14 C-BIL, radioactivity was rapidly absorbed, with the same mean T max values for both total radioactivity and immunoreactive BIL. AUCs for immunoreactive BIL were 41% and 16% of those for circulating 14 C after intravenous and subcutaneous dosing, respectively ( Fig. 1; Table 1 ). AUCs for immunoreactive BIL were 63% and 31% of those for circulating 125 I after intravenous and subcutaneous dosing, respectively. The subcutaneous bioavailability of BIL was 23%-29%, and it was determined on the basis of comparison of the AUC of 14 C radioactivity after intravenous and subcutaneous administration that ;75% of the dose was absorbed. After subcutaneous dosing, the AUC of In the unconjugated PEG study, following the subcutaneous dose, the highest mean concentrations of radioactivity in plasma were at 10.5 hours after dosing ( Fig. 2; Table 1 ). Of note is that the first sample was not collected until 6 hours after dosing in this study. After subcutaneous and intravenous administration, radioactivity was eliminated from plasma with a mean t 1/2 of 202 6 27 hours and 165 6 8 hours, respectively, which was similar to that for (Fig. 3 ). 14 C radioactivity was eliminated slowly in both urine and feces and was still being eliminated in both urine and feces at the end of the 2-week sample collection period after the intravenous and subcutaneous doses. Because sample collection was terminated after 2 weeks (,5 elimination t 1/2 s for 14 C in serum), between 32% and 40% of the 14 C dose was found either in the carcass or in the cage rinses/washes. 125 I radioactivity was eliminated rapidly; after intravenous and subcutaneous administration, ;91%-98% of the administered radioactive dose was recovered by 72 hours after dosing, primarily in urine. Immunoreactive BIL was excreted more rapidly than the ]BIL ranged from 7.24%-29.8%, indicating that radioactivity in urine was primarily associated with small peptide fragments or free iodine, rather than with labeled intact BIL or tyrosinecontaining peptides attached to the 20-kDa PEG moiety. For the unconjugated PEG study, urinary excretion was the primary route of elimination for 14 C (Fig. 4) . Some radioactivity was still being excreted 2 weeks after dosing, although the majority of the elimination occurred within the first 72 hours after dosing. Sample collection was terminated after 2 weeks, which was ,5 plasma elimination t 1/2 s. At the end of the sample collection period, 62%-86% of the 14 C dose of unconjugated PEG had been recovered in urine and feces. Fig. 5 .
Catabolism Products. The catabolism products of BIL in serum and urine were characterized following subcutaneous administration by using MS. BIL was identified using the specific ion trace of 1821.53 amu corresponding to the A-chain + the B-chain B27 ion in the ISF MS/MS spectra. PEG-lysine is 20-kDa PEG covalently linked to lysine and was a potential catabolism product of BIL. Standards of BIL and PEG-Lys were used to establish retention times and spectral differentiation. Urine sample analyses showed that BIL was detectable only in the 0-to 12-hour urine samples even though it was quantifiable at additional time points using the ELISA. This difference was because of the higher detection limit in the MS analyses (15.5 nM) than in the ELISA (30 pM).
In addition to BIL, a second peak at 12.5 minutes was detected in the urine samples through 240 hours. Figure 6 shows zoomed spectra for the 12.5-minute PEGylated peak compared with BIL, PEG-Lys, and 20-kDa PEG. The spectra show that the peak corresponds to PEGLys. The intact spectra confirmed the assignment, although the MS/MS spectra of the product were insufficient. No other catabolism product was observed in the urine samples.
Serum samples analyzed by intact analyses showed that BIL was detected at 9-10 minutes but only through 12 hours. BIL was detectable in serum using the ELISA for much longer times. The lower limit of quantitation for the serum ELISA was 75 pM and that for the MS was 15.5 nM. ISF data showed the presence of a PEGylated catabolism product; however, identification could not be confirmed because of low signal relative to BIL. The PEGylated product did not contain the B-chain because of the lack of a distinctive signal at 875.4 amu. No other long-chain amino acids were detected in the serum, most likely indicating that the catabolism product was PEG-Lys.
Exploratory size-exclusion chromatography of urine from the rats receiving unconjugated [ 14 C]PEG indicated that the 20-kDa PEG remained intact, similarly to after BIL dosing (data on file, Eli Lilly and Company).
Discussion
BIL is a novel, PEGylated insulin lispro that has a large hydrodynamic size. It has a prolonged duration of action that is related to a delay in insulin lispro absorption and a reduction in CL . The fate of therapeutic proteins is generally thought to be via catabolism to small peptides and amino acids, but the biologic fate of PEGylated proteins has not been well studied because of the difficulties in quantifying PEG. The fate of a 40-kDa PEG attached to insulin has been determined by using immunoblotting with antibodies to PEG combined with NMR spectroscopy (Elliott et al., 2012) , and the tissue uptake of 40-kDa branched PEG on Adnectin was determined by using a 14 C-labeled cross-linker on 40-kDa branched PEGylated Adnectin (Wang et al., 2012a) . The disposition of [
14 C]peginesatide, a 2 Â 20-kDa PEGylated erythropoietin, after intravenous administration to rats and monkeys has been reported (Woodburn et al., 2012 (Woodburn et al., , 2013 ; renal excretion of the parent molecule was the primary route of elimination. Zou et al. (2013) reported that for a 46-kDa PEGylated [ 3 H]neuromedin-U receptor agonist the primary route of elimination in both rats and dogs was urinary excretion of the parent molecule, although recovery of radioactivity ranged from 38%-80%.
In our studies, we administered [ 14 C]PEG-labeled BIL and [ 125 I] lispro-labeled BIL to assess the biologic fate of both the protein and 20-kDa PEG portions of BIL. We also determined the PK of the intact molecule (immunoreactive BIL) with a validated ELISA. By tracking the intact molecule using ELISA, the PEG moiety and its products using 14 C, and the protein moiety and its products using 125 I, in addition to MS for PEG products, we were able to determine the disposition of BIL and to determine its catabolism products. Finally, we compared the biologic fate of 14 C-labeled unconjugated 20-kDa PEG with [
14 C]PEG-labeled BIL to assess how the disposition of 20-kDa PEG is influenced by the attached protein.
Following administration of labeled BIL, greater systemic exposure and longer t 1/2 were observed for 14 C than for 125 I, which indicates that the 125 I or the protein portion (lispro) of BIL (containing the labeled tyrosine residues) was cleaved from the PEG moiety. MS indicated that the 20-kDa PEG primarily retained a lysine. The resulting PEG-lysine product was cleared more slowly than the protein portion of BIL. The t 1/2 of 14 C after BIL dosing was similar to the t 1/2 of 14 C after unconjugated PEG dosing. The 23%-29% bioavailability of radiolabeled BIL and the .75% absorption of 14 C indicate extensive catabolism of BIL. This is also shown by the low percentage of the circulating 125 I and 14 C that is present as intact BIL. Therapeutic biologic drugs are generally eliminated via catabolism to smaller peptides and amino acids, but little information is available on whether this occurs presystemically or after absorption. In the case of BIL, it appears that catabolism is at least partially presystemic in rats; similar results have been reported for PEGylated erythropoietin in rats (Wang et al., 2012b) . The presystemic catabolism in rats appears to be higher than in humans; the subcutaneous bioavailability of BIL in humans was reported to be 75% .
After administration of [ 14 C]BIL, the radioactivity recovered in the urine was primarily PEG-lysine, indicating that the 20-kDa PEG moiety did not undergo catabolism and that the catabolism was primarily via proteolysis on the protein moiety in BIL. Through a comparison of circulating BIL, 125 I, and 14 C, PEG-lysine also appeared to be a major contributor to the circulating radioactivity, although this could not be confirmed with MS because of the high MS detection level of PEGylated products in serum. Unconjugated 20-kDa PEG also did not appear to undergo catabolism but was excreted in urine primarily unchanged (data on file, Eli Lilly and Company). These data are (Fishburn, 2008 ). This appears to be the case whether the PEG is unconjugated or conjugated to a protein such as lispro. Thus, the ]BIL. "Other" includes the residual radioactivity in the carcass at the end of the 2 weeks. Samples were collected for 2 weeks, but urine and feces would need to be collected for ;40 days to obtain full recovery in excreta based on 5 elimination t 1/2 s. in serum after 14 days; ;13%-40% of the dose remained in the carcasses at 336 hours after dosing. Termination of the sample collection after ,5 elimination t 1/2 s, or at least 40 days, resulted in less than full recovery in urine and feces. Radioactivity was still being eliminated in urine and feces at the end of the 2 weeks, which was not unexpected given the long elimination t 1/2 for 14 C. The recovery of total radioactivity in other studies with PEGylated molecules has been reported to be similarly low: 38%-80% for 46-kDa PEGylated [ 3 H]neuromedin-U receptor agonist in rat and dog (Zou et al., 2013) and 53%-67% for 2 Â 20-kDa PEGylated [ 14 C] peginesatide in rats and monkeys (Woodburn et al., 2012 (Woodburn et al., , 2013 . In a study with nonradiolabeled 2 Â 20-kDa PEG insulin, Elliott et al. (2012) reported recovery of 35%-47% of the PEG dose in urine after 28 days. These studies and ours demonstrate the difficulty of obtaining complete recovery of the dose when PEGylated molecules are administered.
The dose of the unconjugated 20-kDa PEG was higher than the PEG dose in BIL due to the differences in specific activity of the dose and the difficulty in measuring unconjugated PEG. The use of a higher dose of unconjugated PEG did not appear to alter the elimination of the unconjugated 20-kDa PEG from being primarily urinary. As indicated in the literature, urinary excretion has been reported to be the major elimination route for PEG moieties of ,50 kDa (Yamaoka, et al., 1994; Webster et al., 2007) . In contrast, when the 20-kDa PEG was covalently attached to lispro in BIL, the PEG appeared to be excreted about equally in urine and feces, even though examination of circulating and urinary products did not seem to show that it had been catabolized. In vitro experiments have also shown that the 20-kDa PEG in BIL is recycled out of the cells and is not catabolized (Kiselyov et al., 2014) . Fecal and urinary excretion were important routes of elimination for [
14 C]BIL-related radioactivity after a single subcutaneous or single intravenous dose in rats. These differences between the excretion of PEG administered alone or as part of BIL indicate that the biologic fate of the PEG is directed, at least in part, by the insulin-receptor interactions and subsequent intracellular protein degradation that occur with BIL but not with unconjugated PEG.
Mass balance studies in humans with 14 C-radiolabeled BIL are not feasible because only low doses (typically ,9 nmol/kg) of BIL could be administered without hypoglycemia occurring and because high specific activity would be necessary for detection of radioactivity at such low doses. The dose of 2 mg/kg (77 nmol/kg or 8.6 U/kg) BIL s. c. chosen for the rats was the high dose that was used in toxicology studies and was much higher than the doses that are administered therapeutically. The higher dose in the rats was a dose used in the 6-month toxicology studies demonstrating dose linearity in the exposure of basal insulin peglispro (data on file, Eli Lilly and Company). The excretion observed in the rats is expected to be predictive of the excretion in humans; therefore, in humans, the PEG in BIL would be expected to be eliminated via urine and feces. There are limited data in the literature regarding the excretion profiles of PEG molecules in humans; however, it has been hypothesized that the size of the PEG moiety determines the elimination route, i.e., via urine and/or feces (Webster, et al., 2007) . This study in rats demonstrates that the size of the PEG is only one determinant of the excretion and that the protein attached to the PEG moiety may play a more important role in the elimination. Thus, to understand the biologic fate/ elimination of PEG in a given PEGylated biopharmaceutical agent, studies specific to the molecule are needed because the polypeptide component may influence the balance between the routes of excretion.
Together, the data suggest that elimination of PEG derived from BIL in rats is by both biliary and renal routes. Although studies with radiolabeled BIL are not feasible in humans, we would anticipate a similar observation: that PEG in BIL has two routes of elimination, nonrenal and renal, and that the lispro portion of BIL would be eliminated renally as small peptides and/or amino acids.
